Healthcare has historically been a service, with costs tied to licensed professionals. AI models like Gemini and ChatGPT are changing this by providing medical advice, effectively turning healthcare into a product. This shift, currently tolerated by regulators, could dramatically lower costs and increase access, just like software products.

While clinical AI is promising, the most immediate ROI is in tackling the $1 trillion in administrative waste (20-25% of total costs). AI can automate friction points like scheduling and prior authorizations, directly improving the patient experience and bending the cost curve.

Resource-constrained startups are forgoing traditional hires like lawyers, instead using LLMs to analyze legal documents, identify unfavorable terms, and generate negotiation counter-arguments, saving significant legal fees in their first years.

The immense regulatory complexity in U.S. healthcare creates an estimated $500 billion "tax" of administrative bloat. The non-obvious opportunity is that by using AI to eliminate this waste, the savings could be redirected to fund expanded patient care, rather than just being captured as profit.

The most significant immediate benefit AI can offer the public is halving healthcare costs. This can be achieved by automating primary care workflows, but it requires legislative innovation. Creating state-level 'AI sandboxes' would allow companies to safely prove out specific use cases and accelerate adoption.

The most tangible ROI for AI in healthcare today isn't in complex diagnostics, but in operational efficiency. AI scribes that free up doctors, intelligent call centers that triage patients correctly, and automated claim management are solving major bottlenecks and fighting burnout right now.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.

While AI for designing novel molecules gets the hype, its practical, near-term impact is in streamlining operational tasks like summarizing medical charts, preparing SEC filings, and analyzing contracts, which are a better fit for current LLM capabilities.

The business case for AI is strong, as executing a task for $2-$5 via AI can save an enterprise $55. This significant return on investment suggests companies are financially motivated to increase, not decrease, their spending on AI services over time, despite current market concerns.